Phase III Trial

Latest news

Tag

Neoadjuvant Intralesional Daromun Significantly Improves Outcomes in Resectable Stage III Melanoma: Insights from the PIVOTAL Phase III Trial Update

Updated PIVOTAL Phase III trial data demonstrate that neoadjuvant intralesional Daromun significantly improves recurrence-free and distant metastasis-free survival in resectable stage III melanoma without new safety concerns at 36.8 months

Aug 13, 2026

news

Eryaspase Fails to Improve Survival in Second‑Line Advanced Pancreatic Cancer: Results from the Phase III TRYBECA‑1 Trial

In TRYBECA‑1, adding erythrocyte‑encapsulated L‑asparaginase (eryaspase) to second‑line chemotherapy did not improve overall survival, progression‑free survival, or response rates in advanced pancreatic ductal adenocarcinoma; adverse events

Dec 8, 2025

Clinical Updates

Xevinapant Fails to Improve Outcomes in Locally Advanced Head and Neck Cancer: Insights from the Phase III TrilynX Trial

The TrilynX phase III study showed that adding xevinapant to platinum-based chemoradiotherapy did not improve event-free survival and was associated with worse overall survival and higher toxicity in unresected locally advanced squamous cel

Sep 8, 2025